Iressa Versus Docetaxel (Taxotere)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00076388 |
Recruitment Status :
Completed
First Posted : January 23, 2004
Last Update Posted : May 13, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-Small-Cell Lung Carcinoma | Drug: Gefitinib Drug: Docetaxel | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 1440 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy |
Study Start Date : | February 2004 |
Actual Primary Completion Date : | March 2007 |
Actual Study Completion Date : | October 2007 |
- To compare overall survival between ZD1839 and docetaxel
- To compare time to progression (TTP) between ZD1839 and docetaxel
- To compare progression-free rates at 4 months and 6 months between ZD1839 and docetaxel
- To compare the overall objective tumor response rate between ZD1839 and docetaxel
- To compare patient-reported functionality (PRF) and quality of life (QoL) between ZD1839 and docetaxel
- To compare safety and tolerability of ZD1839 and docetaxel
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Measurable (uni dimensional) disease by RECIST criteria in a lesion not previously irradiated or non measurable disease
- Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy
- Advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based chemotherapy
- WHO performance status (PS) 0-2
- Absolute Neutrophil Count (ANC) >1.5 x 109/liter (L) and platelets >100 x 109/L
- Life expectancy of at least 8 weeks
Exclusion Criteria:
- Prior ZD1839 therapy
- Prior docetaxel treatment for NSCLC
- Less than 14 days since completion of prior radiotherapy
- Less than 21 days since prior chemotherapy, immunotherapy or biological systemic anticancer therapy
- Evidence of clinically active Interstitial Lung Disease
- Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
- Newly diagnosed CNS metastases that have not yet been treated with surgery and/or radiation. Patients with previously diagnosed and treated CNS metastases or spinal cord compression may be considered if they have evidence of clinically SD (no steroid therapy or steroid dose being tapered) for at least 28 days
- Patients with pre existing peripheral neuropathy >= grade 2 (NCI CTC criteria)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00076388
Study Director: | AstraZeneca Iressa Medical Science Director, MD | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00076388 |
Other Study ID Numbers: |
D791GC00001 EudraCT No: 2004-002943-28 1839IL/0721 |
First Posted: | January 23, 2004 Key Record Dates |
Last Update Posted: | May 13, 2011 |
Last Verified: | May 2011 |
Non-Small-Cell Lung Cancer |
Carcinoma, Non-Small-Cell Lung Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |
Docetaxel Gefitinib Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Tyrosine Kinase Inhibitors Protein Kinase Inhibitors Enzyme Inhibitors |